StockNews.AI
ALNY
StockNews.AI
143 days

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

1. Alnylam presented new Phase 3 trial data on vutrisiran at ACC.25. 2. The trial focuses on ATTR amyloidosis with cardiomyopathy, relevant to current patients.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive presentation of Phase 3 data can enhance ALNY's market position, similar to past successful clinical data announcements that boosted stock prices.

How important is it?

The data from a significant Phase 3 trial showcases ALNY's ongoing innovation and therapeutic advancements, crucial in attracting investor interest.

Why Short Term?

Immediate market reactions are expected from the trial results, akin to past events where new data influenced investor sentiment quickly.

Related Companies

NVSBMYAMGN
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois.

Related News